434 related articles for article (PubMed ID: 32528868)
1. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.
Hau PM; Lung HL; Wu M; Tsang CM; Wong KL; Mak NK; Lo KW
Front Oncol; 2020; 10():600. PubMed ID: 32528868
[TBL] [Abstract][Full Text] [Related]
2. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
4. Latent Membrane Protein 1 Is a Novel Determinant of Epstein-Barr Virus Genome Persistence and Reactivation.
Caves EA; Butch RM; Cook SA; Wasil LR; Chen C; Di YP; Lee N; Shair KHY
mSphere; 2017; 2(6):. PubMed ID: 29134204
[TBL] [Abstract][Full Text] [Related]
5. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.
Hutajulu SH; Kurnianda J; Tan IB; Middeldorp JM
Ther Clin Risk Manag; 2014; 10():721-36. PubMed ID: 25228810
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus infection and nasopharyngeal carcinoma.
Tsao SW; Tsang CM; Lo KW
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
[TBL] [Abstract][Full Text] [Related]
9. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
Brooks L; Yao QY; Rickinson AB; Young LS
J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
[TBL] [Abstract][Full Text] [Related]
11. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Assessing the Clinical Implications of Epstein-Barr Virus Infection and Their Application to the Diagnosis and Treatment of Nasopharyngeal Carcinoma.
Yoshizaki T; Kondo S; Dochi H; Kobayashi E; Mizokami H; Komura S; Endo K
Microorganisms; 2023 Dec; 12(1):. PubMed ID: 38276183
[TBL] [Abstract][Full Text] [Related]
13. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.
Borozan I; Zapatka M; Frappier L; Ferretti V
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093097
[TBL] [Abstract][Full Text] [Related]
15. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.
Guo X; Li T; Li F; Xu Y; Wang H; Cheng W; Tang J; Zhou G; Chen H; Ng M; Ji M; Ge S; Xia N
Oral Oncol; 2019 Jun; 93():85-90. PubMed ID: 31109701
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
[TBL] [Abstract][Full Text] [Related]
17. EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells.
Huo S; Luo Y; Deng R; Liu X; Wang J; Wang L; Zhang B; Wang F; Lu J; Li X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122398
[TBL] [Abstract][Full Text] [Related]
18. [Expression of Epstein-Barr virus genes in EBV-associated gastric carcinoma].
Wang Y; Luo B; Zhao P; Huang BH
Ai Zheng; 2004 Jul; 23(7):782-7. PubMed ID: 15248912
[TBL] [Abstract][Full Text] [Related]
19. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism.
Wang C; Wang H; Zhang Y; Guo W; Long C; Wang J; Liu L; Sun X
Oncol Rep; 2017 Apr; 37(4):2109-2120. PubMed ID: 28259949
[TBL] [Abstract][Full Text] [Related]
20. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
